Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
NCT01132625
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Interventions
DRUG:
AUY922
Sponsor
Novartis Pharmaceuticals